🔬 Pharmidex is proud to advance the frontiers of drug discovery 🔬
June 23, 2025

With our cutting-edge in silico drug discovery capabilities 👉 https://www.pharmidex.com/In-silico


Pharmidex   is committed to accelerating the development of novel therapies targeting GLP-1 receptors, a promising path in the fight against obesity and type 2 diabetes.

By combining our in silico expertise, including molecular docking, virtual screening and structure-based design, with our well-established in vivo obesity models, we offer a powerful, integrated platform to uncover and validate new therapeutic candidates more efficiently.


Whether you're a pharma company, CRO, biotech, or academic institution, Pharmidex is ready to collaborate and support your discovery efforts from computational predictions to real-world preclinical validation.


🤝 Let’s combine strengths and accelerate innovation in metabolic disease research to improve human health globally.


#DrugDiscovery #GLP1 #InSilico #Pharmidex #ObesityResearch #Diabetes #PreclinicalResearch #AIinDrugDiscovery #PharmidexInSilico #InVivoModels #GLP1Receptor

February 17, 2026
We’re proud to announce that Pharmidex has joined the Good Clinical Practice (GCP) Network , a global collaboration advancing ICH-GCP excellence in clinical research. For us, quality and data integrity are not box-ticking exercises, they are fundamental to credible science and responsible drug development. From pre-clinical research through to clinical delivery, we are committed to: • Regulatory rigour • Ethical conduct • Participant protection • Scientifically robust data Joining the GCP Network further strengthens that commitment. We look forward to contributing to a global community dedicated to raising the bar across clinical research.
February 12, 2026
Pharmidex now offers integrated in vivo CAR-T study support , combining robust in-life pharmacology with advanced f low cytometry –based cellular analysis. We support early-stage CAR-T and cell therapy programmes with translational data on efficacy, expansion, persistence and phenotype delivered through a single collaborative CRO partner. Let’s talk. 🌐 www.pharmidex.com
February 11, 2026
Pharmidex is pleased to share that Janette Dalay Robertson will be attending the Founders Growth Community Meeting and Networking x Innovate Cambridge event at The Glasshouse, Cambridge. Janette will be available to meet between 12:00–15:30 and looks forward to connecting with fellow attendees to explore new alliances in pre-clinical and clinical drug development. If you’re attending, let’s connect.
More Posts